Imagine knowing years in advance when an asthma attack might strike. Sounds like science fiction, right? But groundbreaking research is turning this into a reality. Scientists at Mass General Brigham and Karolinska Institutet have developed a method that can predict asthma attacks up to five years ahead with remarkable accuracy. Their findings, published in Nature Communications (http://doi.org/10.1038/s41467-025-67436-7), could revolutionize how we manage this chronic condition affecting over 500 million people worldwide.
Asthma attacks are not only terrifying for patients but also a significant burden on healthcare systems. Despite its prevalence, doctors currently lack reliable tools to identify who’s at high risk. Traditional methods often fail to distinguish between stable patients and those on the brink of a severe episode. And this is the part most people miss: without early warning signs, interventions are often reactive rather than preventive.
So, how did the researchers crack this code? They analyzed data from over 2,500 asthma patients across three large cohorts, leveraging decades of electronic medical records. Using a cutting-edge technique called metabolomics, they measured tiny molecules in the blood called metabolites. Here’s where it gets fascinating: they discovered a critical relationship between two types of metabolites—sphingolipids and steroids—and asthma control. Specifically, the ratio of sphingolipids to steroids proved to be a powerful predictor of exacerbation risk over five years. In some cases, this model could pinpoint the time to a first attack with nearly a year’s difference between high- and low-risk groups.
But here’s where it gets controversial: while individual metabolite levels offered some clues, it’s the ratio between these molecules that truly matters. This finding challenges the conventional focus on single biomarkers and opens the door to a more nuanced understanding of asthma. As co-corresponding author Jessica Lasky-Su, ScD, explains, “Our findings solve a critical unmet need. By measuring this balance, we can identify high-risk patients with 90% accuracy, allowing clinicians to intervene before an attack occurs.”
Craig E. Wheelock, Principal Researcher at Karolinska Institutet, adds, “The interaction between sphingolipids and steroids drives the risk profile. This ratio approach is not only biologically meaningful but also analytically robust, making it highly suitable for a practical, cost-effective clinical test.”
This breakthrough could pave the way for precision medicine in asthma management. A simple blood test based on these ratios could be easily integrated into standard lab procedures, helping doctors spot seemingly stable patients with hidden metabolic imbalances. But before you get too excited, there’s a catch: the method still needs further validation through clinical trials and cost-effectiveness analyses before it can be widely adopted.
Now, here’s a thought-provoking question for you: If this test becomes available, would you want to know your asthma attack risk years in advance? Or do you think such knowledge could lead to unnecessary anxiety? Let us know in the comments!
For the curious minds, the study was a collaborative effort between Karolinska Institutet and Mass General Brigham, funded by the National Heart, Lung, and Blood Institute (NHLBI), the Swedish Research Council, and the Swedish Heart-Lung Foundation. The researchers have applied for a patent on the method, and disclosures include Jessica Lasky-Su’s advisory roles with Precion Inc. and TruDiagnostic Inc., as well as Scott T. Weiss’s royalties from UpToDate and board position at Histolix. The full paper, “The ratio of circulatory levels of sphingolipids to steroids predicts asthma,” is available in Nature Communications (DOI: 10.1038/s41467-025-67436-7).
